glp 1 nausea and vomiting GLP-1 Dry Mouth, Bad Breath, & Taste Changes: What Actually Helps? GLP1 SIDE EFFECTS: Gene Variation

Interestingly, NPY has been reported to increase neurogenesis in the dentate gyrus (Malva et al., 2012)

Accordingly in the present study, LVEF decline is associated with atrial glutathione deficiency in CAD patients (r = 0.45

Skin-enhancing peptides These therapies are often personalised following health checks and used in combinations or cycles with active medical guidance

CagriSema vs Comparators Feature Receptor targets CagriSema Amylin/calcitonin + GLP-1 Tirzepatide (Zepbound) GIP + GLP-1 Semaglutide alone (Wegovy) GLP-1 Cagrilintide alone Amylin/calcitonin (DACRA) Feature Dosing frequency CagriSema Once weekly Tirzepatide (Zepbound) Once weekly Semaglutide alone (Wegovy) Once weekly Cagrilintide alone Once weekly Feature Maintenance dose CagriSema 2.4 mg + 2.4 mg Tirzepatide (Zepbound) Up to 15 mg Semaglutide alone (Wegovy) 2.4 mg Cagrilintide alone 2.4 mg (in REDEFINE arms) Feature Headline weight loss CagriSema 20.4% at 68 wks (REDEFINE 1, treatment-policy) Tirzepatide (Zepbound) Up to 22.5% at 72 wks (SURMOUNT-1, 15 mg arm) Semaglutide alone (Wegovy) 14.9% at 68 wks (REDEFINE 1 reference arm) Cagrilintide alone 11.5% at 68 wks (REDEFINE 1 reference arm) Feature FDA status (June 2026) CagriSema NDA filed Dec 2025

PlexusDx compounded semaglutide injection therapy allows flexible dosing adjustments